IMGN is a reasonable choice, but my pick is ALNY. ALNY has in-licensed so much IP from third parties that any royalties they eventually keep on the 31 drug targets licensed to NVS will more than likely be de minimis. I wouldn’t be surprised if ALNY has to pass through 75%+ of gross royalties it earns from NVS.
Market Data 
Markets 
AI
